Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer

NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into an R&D agreement with PerkinElmer Health Sciences to design an assay for evaluating a patient's risk of developing hepatocellular carcinoma.

The assay will be based on Trovagene's TrNA technology, the company said in a document filed with the US Securities and Exchange Commission, adding that both firms will jointly validate the assay and evaluate the possibility of combining the TrNA technology with PerkinElmer's technology for automation of nucleic acid isolation.

Trovagene's TrNA, or transrenal nucleic acid, testing technology is based on a method of nucleic acid isolation followed by the detection of specific genetic markers. The technology, according to the San Diego-based firm, can be used for a broad variety of medical conditions.

Under the terms of the deal, PerkinElmer will pay Trovagene milestone payments. PerkinElmer also has received an exclusive option to obtain a royalty-bearing license to use Trovagene's technology within the area of hepatocelluar carcinoma, as well as an exclusive option to obtain a royalty-bearing license to use Trovagene's technology in fields other than hepatocellular carcinoma.

Under certain conditions Trovagene has the option to obtain a royalty-bearing license to PerkinElmer's interest in any invention and/or intellectual property.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.